�The ability of profligate
tests to precisely measuring very depleted doses of anti-rejection drugs in kidney
transplant patients may make a meaning difference in assuring long-term
viability and survival, according to research presented at the
American Association for Clinical Chemistry (AACC) annual meeting.
The current mentation in transpose medicine favors reducing doses of
tacrolimus and other immune-suppressive drugs as a great deal as possible after
kidney-transplant procedures. "Even though we are succeeding in preventing
organ rejection, we haven't made much progress to improve long-term
survival," said Sudarshan Hebbar, M.D., elderly medical conductor, Abbott
Diagnostics. "Unfortunately, most kidney transplant patients volition go back
on dialysis in eight to ten years, in part because the anti-rejection drugs
tin be toxic to the kidneys."
Dr. Hebbar added that kidney-transplant patients stimulate high incidence of
